Pharvaris NV

09/13/2024 | Press release | Archived content

Long Term Safety and Efficacy of Prophylactic Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Hereditary Angioedema: Results of the CHAPTER 1 Open Label Extension Study